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Poxvirus genomes encode several proteins which inhibit specific elements of the host immune response. We show the
‘‘35K’’ virulence gene in variola and cowpox viruses, whose vaccinia and Shope fibroma virus equivalents are strongly
conserved in sequence, actually encodes a secreted soluble protein with high-affinity binding to virtually all known b
chemokines, but only weak or no affinity to the a and g classes. The viral protein completely inhibits the biological activity
of monocyte chemotactic protein-1 (MCP-1) by competitive inhibition of chemokine binding to cellular receptors. As all b
chemokines are also shown to cross-compete with MCP1 binding to the viral protein, we conclude that this viral chemokine
inhibitor (vCCI) not only interacts through a common binding site, but is likely a potent general inhibitor of b chemokine
activity. Unlike many poxvirus virulence genes to date, which are clearly altered forms of acquired cellular genes of the
vertebrate immune system, this viral chemokine inhibitor (vCCI) shares no sequence homology with known proteins, including
known cellular chemokine receptors, all of which are multiple membrane-spanning proteins. Thus, vCCI presumably has no
cellular analogue and instead may be the product of unrelenting sequence variations which gave rise to a completely new
protein with similar binding properties to native chemokine receptors. The proposed function of vCCI is inhibition of the
proinflammatory (antiviral) activities of b chemokines. q 1997 Academic Press
receptors (Symons et al., 1995; Upton et al., 1992), otherINTRODUCTION
TNF receptors (Smith et al., 1996), and inhibitors of IL-1
All viruses which productively infect eukaryotic hosts processing (Ray et al., 1992) underscores the validity of
must possess mechanisms to avoid immune surveillance both points. Collectively termed virulence factors and often
that would otherwise lead rapidly to their elimination (Mar- secreted, these proteins are not required for viral DNA
rack and Kappler, 1994; Smith et al., 1990, 1991). Although replication and usually show clear homology to known
this maxim has been long accepted prima facie, the mecha- genes of the host immune system (Smith and Goodwin,
nisms involved have remained enigmatic until recent years. 1994). One presumed virulence gene, the ‘‘35K’’ gene of
The discovery that an obscure open reading frame, T2, in vaccinia (Patel et al., 1990) and related poxviruses (Hu et
Shope fibroma poxvirus encodes a soluble secreted form al., 1994; Martinez-Pomares et al., 1995), in contrast, shows
of an acquired cellular receptor for tumor necrosis factor no sequence homology with any known proteins and is of
(TNF) proved illuminating for two reasons (Smith et al., 1990, unknown function, although its sequence is strongly con-
served. The 35K gene product of vaccinia (Lister) has been1991). First, it clearly demonstrated that viruses target host
shown to be secreted from infected cells (Patel et al., 1990),cytokine (inflammatory) networks for disruption, the pre-
and like T2, is diploid, with one copy in either of the 10-sumed function of which is to increase virulence. Direct
kb inverted terminal repeats of the large (160 kb) duplexevidence in support of this proposal came from the subse-
DNA genome. To determine its function, we expressedquent demonstration in myxoma poxvirus that targeted in-
epitope-tagged soluble forms of the same protein from vari-activation of the T2 gene reversed virulence by almost 70%
ola virus (vav), the causative agent of smallpox in human,(Upton et al., 1991). Second, it helped to establish viral
and cowpox virus (cpv) and then used these as probes toacquisition of host immune genes themselves, subverted
identify the cognate. We show that both secreted proteins,to viral function, as a general phenomenon, presaged by
84% identical in sequence, actually promiscuously bindthe identification of a vaccinia virus gene with homology to
chemokines of the b class with high affinity, bind at leastcomplement (Kotwal and Moss, 1988; Kotwal et al., 1990).
one a chemokine (IL8) with low affinity, and appear to
The subsequent identification of the T2 gene in virtually all completely inhibit their (proinflammatory) biological activity.
poxviruses and other genes encoding soluble interleukin-1
MATERIALS AND METHODS(IL-1) receptors (Spriggs et al., 1992), a/b- and g-interferon
Plasmid construction
A soluble form of the cowpox vCCI protein fused to1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (206) 233-9733. E-mail: Smithc@immunex.com. the Fc region of human IgG1 was constructed in the
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mammalian expression vector pDC406 (McMahan et al., huMCP3, huRANTES, muMIP1a, b, muC10, huGROa, b,
g, huIL-8, huENA-78, huSDF-1b, huMCP-2, muMIP2,1991). The entire coding region of the cowpox protein
was amplified by PCR using as a template an 11.8-kb muMIP1, muKC, huMIDKINE (R&D Systems, Minneapo-
lis, MN); huMCP4, human and mouse Eotaxin, humanEcoRI fragment of the cowpox genome, which contains
the inverted terminal repeat, subcloned into pBR325 and rat MIP1a, muMCP-5, rat GRO b, rat MCP-1, huMIG
human lymphotactin (PeproTech, Rocky Hill, NJ); human(Pickup et al., 1982). The oligonucleotides used were 5*-
ATAGCGGCCGCATCTAGAACAGCAATCATGAAAC-3*, platelet factor-4 (PF-4), huIP-10, huNAP-2, rat GROa (Bio-
source, Camarillo, CA); huIL-8 (Genzyme, Boston, MAwhich introduces a NotI site upstream of the initiator
methionine, and 5*-GTTAGATCTGGGCTCGACACACGC- and R&D Systems); C5a (Fluka); huIL-16 (AMS Biotech-
nology). Human and murine MCP1 and MIP1a wereTATAAGTTTTGCTG-3*, which inserts the amino acids
Glu, Pro, and Arg after the last amino acid of the 35K shown to be biologically active at subnanomolar levels
with in-house assays. For all others, particularly thoseprotein. Glu and Pro are the first two amino acids of the
hinge region of human IgG1 and are followed by a BglII weak or nonbinding a chemokines, every attempt was
made to ensure the validity of in vitro bioactivity profilessite that was used to fuse the 35K coding region to the
remainder of the Fc domain as previously described offered by the vendors.
Flag octapeptide (Hopp et al., 1988) was synthesized(Fanslow et al., 1992).
An alternative soluble form of cowpox 35K was created by conventional solid-phase synthesis (Applied Biosys-
tems, Foster City, CA) and purified by reverse-phaseby PCR amplification which was tagged with the FLAG
epitope (Hopp et al., 1988) at the 5* end of the mature HPLC on C4 columns. M2 anti-flag monoclonal antibody
was produced at Immunex (Hopp et al., 1988). Polyclonalprotein. The 5* oligo utilized in this PCR was 5*-ATAACT-
AGTGACTACAAGGACGACGATGACAAGCAATCATTC- goat anti-human Fc was purchased from Jackson Immu-
noResearch (West Grove, PA). Purified human IgG1 wasTCATCCTCATCCTC-3*, which adds an SpeI site and the
FLAG coding region and begins with amino acid 22 of produced at Immunex.
the cowpox 35K ORF. The resulting PCR product was
Radiolabeling, immunoprecipitations, and SDS gelinserted behind a CMV open reading frame leader se-
electrophoresisquence as previously described (Wiley et al., 1995).
A soluble form of the variola 35K protein (G5R, India
TE71 cells were cultured in 10-cm petri dishes to near-
1967 strain) (Shchelkunov et al., 1993) was also con-
confluency for 3 days, as described above, washed once
structed. The entire coding region of G5R was recon-
in PBS, and recultured at 377 for 30 min in cysteine/
structed with overlapping oligonucleotides with SalI and
methionine-depleted RPMI medium. Cells were washed
NotI restriction sites appended to the 5* and 3* ends,
once in the same medium and then recultured for 5 hr
respectively, and cloned into pBluescript SK(/) (Stra-
at 377, 10% CO2 in 2 ml of the same medium supple-tagene). This clone was then used as a template for a
mented with 300 mCi of 35S Translabel (Amersham). The
PCR which removed the termination codon and inserted
labeled supernatant was precleared by overnight incuba-
a BglII site that was used to fuse the 35K coding region
tion at 47 with 1 ml PBS/0.5% NP-40 containing 5 mg/
with the Fc domain as described above.
ml huIgG1 and 0.2 ml of a 20% protein G suspension
Isolation of the fusion proteins was performed by tran-
(Pharmacia, Piscataway, NJ) in the same buffer. Protein
sient expression in CV1/EBNA cells (ATCC CRL 10478)
G was removed by centrifugation at 3000 rpm for 2 min,
and purification on a protein G–Sepharose column as
and the supernatant was incubated for 7 hr at 47 with 5
previously described (Fanslow et al., 1992). The flag-
mg/ml of cpv p32/Fc (or IgG1 as control) with 1/10 vol
tagged cpv p32 protein was affinity-purified using M2
of 20% protein G suspension again. Immunoprecipitates
(anti-flag) monoclonal antibody and acid (pH 3.0) elution.
were collected by centrifugation, washed three times
The binding activities of cpv flag-p32, cpv p32/Fc, and
with RIPPA buffer (150 mM NaCl, 50 mM Tris, pH 7.5,
vav G5R/Fc were completely stable to acid conditions
0.5% deoxycholate, 0.5% Nonidet-P40, 0.1% SDS) and re-
(not shown).
suspended in Laemmli buffer (Laemmli, 1970), electro-
phoresed through an 8–16% SDS gel, and the dried gel
Cell lines, antibodies, and recombinant chemokines was PhosphorImaged (Molecular Devices, Palo Alto, CA).
The TE71 murine thymic epithelial line was grown to Affinity chromatography and protein sequencing
near-confluence in RPMI 1640 medium (GIBCO, Gaith-
ersburg, MD) supplemented with 1% low-endotoxin fetal Purification of cpv p32 cognates from TE71 condi-
tioned medium was effected by affinity chromatographycalf serum, 100 mg/ml penicillin, 100 mg/ml streptomycin,
and 2 mM L-glutamine at 377 in a humidified, 7% CO2 on cpv p32/Fc-coupled Affigel 10 (Bio-Rad, Richmond,
CA). p32/Fc was coupled to Affigel 10, according to theatmosphere. Conditioned medium were harvested at 4
days, 0.2 mm filtered, and stored at 0207 in aliquots. manufacturer’s instructions, at 5 mg cpv p32/Fc per 1 ml
gel. A preclearing column of huTNFRII/Fc was similarlyAll recombinant chemokines and cytokines were pur-
chased from commercial vendors: hu and muMCP1, constructed. TE71 CM (2.1 liters) was twice passed
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through a 1-ml p32/Fc column and the flow-through was Probes, Eugene, OR), washed 21 with medium and then
seeded at 5 1 105 cells/ml in 8-well glass slides (Nuncsubsequently passed through the p32/Fc column. The
column was then washed with a cocktail of protease Inc., Naperville, IL) precoated with poly-L-lysine (Sigma,
St. Louis, MO). Cells were then allowed to settle andinhibitors (1 mM PMSF, 1 mM pepstatin A, 10 mM leupep-
tin, 2 mM O-phenanthroline) in PBS, 150 ml PBS, and loosely attach to the substrate for 30 min at 377. Slides
were examined in a Molecular Dynamics (Sunnyvale, CA)bound protein was eluted with 1.5-ml fractions of 50 mM
citrate buffer, pH 3.0. Fractions were assayed for protein confocal laser scanning microscope employing a kryp-
ton/argon laser (488 nm excitation; 526 nm emission)on SDS gels, and individual bands were blotted onto
PVDF and sequenced on an Applied BioSystems 477A maintained at 377 throughout the experiment. Prior to
addition of agonists, multiple scans were averaged tosequencer. The 55-kDa band was determined to be con-
taminating albumin, but the diffuse 30-kDa and sharp establish baseline fluorescence; following addition,
scans were recorded at 5-sec intervals. Images were8- to 10-kDa bands were N-terminally blocked. CNBR
digestion was then performed in situ (March et al., 1985) processed to assess mean fluorescence intensity (MFI)
using the IMAGE program (Wayne Rasband, NIH), pub-and the resulting fragments were sequenced without fur-
ther modification. Multiple amino acids were detected in licly available through the Internet (zippy.nimh.nih.gov).
each cycle. The major sequence for cycles 10–24 was
BLAST searched against the nonredundant protein se- Binding and inhibition assays
quence database maintained at the National Center for
Murine MCP1 was radiolabled with 125I (Amersham)Biotechnology Information. An identical match to resi-
using a solid-phase chloramine T analogue (Iodogen,dues 82–96 of mouse mature MCP1 was obtained. With
Pierce, St. Louis, MO) to a specific activity of 3 1 1016this information, the sequence data were further ana-
cpm/mmol, with a minor loss of specific activity (assessedlyzed and sequences corresponding to residues 20–21,
by inhibition with unlabeled MCP1). Equilibrium binding23–50, and 73–99 of mouse mature MCP1 were identi-
assays on THP1 cells were performed in 96-well microti-fied. The CNBr fragment corresponding to residues 1–
ter trays (Corning) as described (Smith et al., 1990). Briefly,19 of mature MCP1 was not identified, but residue 1
serial dilutions of 125I-muMCP1 in binding medium (RPMIis predicted to be pyroglutamate, which is refractive to
1640, 2.5% BSA, 20 mM HEPES, 0.02% sodium azide, pHEdmann N-terminal sequencing. Previous characteriza-
7.2), supplemented with 0.5 mg/ml huIgG1 and 5% humantion of recombinant muMCP1 transiently expressed in
serum, were incubated with cells (2.5 1 106/well) for 2 hrmammalian cells shows that both diffuse (glycosylated)
at 47 in a total volume of 150 ml. Free and bound probes30-kDa protein and sharp (unglycosylated) 8- to 10-kDa
were separated by microfugation through a phthalate-protein are produced, which also differ in the extent of
oil separation mixture and counted in a gamma counter.proteolytic processing (Rollins et al., 1988).
Inhibition assays used 125I-MCP1 at a constant concentra-
tion of 0.5 nM in the presence or in the absence of serialChemotaxis assays
dilutions of potential inhibitors. Nonspecific binding was
Human peripheral blood mononuclear cells (PBMC) determined in the presence of a 100-fold excess of unla-
were isolated from human donors as described (Smith beled MCP1. Theoretical curves based on single-site
et al., 1993). The chemotaxis assay (Martinet et al., 1994) competitive inhibition model were fitted to the data as
was performed in modified Boyden chambers (24-well described (Dower et al., 1984). Percentage inhibition was
transwell plates, pore size 5; Costar). Top chambers con- calculated according to the equation
tained 5 1 106 PBMC, and bottom chambers contained
50 ng/ml recombinant huMCP1 with either cpv p32/Fc I(%)  [100 Ki(I)]/[1 / Ka(L) / Ki(I)],
(166, 500 or 1500 ng/ml) or huIgG at corresponding dilu-
tions as controls. All samples were assayed in triplicate.
where I is the molar concentration of inhibitor, L is the
After incubations for 1 hr at 377, transwell inserts were
molar concentration of radiolabeled ligand, and Ki andremoved and the cells (monocytes) that migrated to the
Ka are the affinity constants of inhibitor and ligand, re-bottom well were counted. Migrations were determined
spectively.
to be chemotactic (directional) not chemokinetic (ran-
Equilibrium binding and competitive inhibition iso-
dom) by examining migration patterns when both cell
therms were also determined in 96-well microtiter plates
number and chemokine concentrations were systemati-
that had been coated with p32/Fc or variola p35/Fc, cap-
cally varied by standard methods. Migration occurred in
tured through goat anti-human Fc polyclonal antibody.
the direction of increasing MCP1 concentrations.
Plates were incubated with 5 mg/ml goat anti-human Fc
in PBS for 4 hr at 47, washed twice with PBS, and thenFluorescence assays
incubated with 0.1 mg/ml Fc chimera in PBS/0.01% Tween
20 for 12 hr at 47 and washed again 21 with PBS. Equilib-THP1 cells were incubated at 377 for 30 min in culture
medium (DMEM, 1% FCS, 20 mM HEPES, pH 7.4) con- rium binding isotherms used serial dilutions of 125I-
muMCP1 in binding medium, and inhibition assays usedtaining 5 mM Fluo-3 acetoxymethyl ester (Molecular
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a constant 0.5 nM 125I-muMCP1 in the presence or in the 35S and CM immunoprecipitated with cpv p32/Fc and IgG
controls (Fig. 2A). p32/Fc specifically bound two proteinsabsence of unlabeled potential competitive inhibitors, as
described above. After 2 hr at 47, plates were washed with an apparent molecular mass of 30 kDa (diffuse) as
well as an 8- to 10-kDa protein. These cognates weretwice in PBS, and specifically bound ligand was released
with 50 mM citrate (pH 3.0) and then gamma counted. then affinity-purified from 2.1 liters of TE71 CM on a p32/
Fc column (Fig. 2B). Twenty micrograms of the purifiedData were processed as described (Dower et al., 1984).
Chemokine binding was also assessed by surface protein was obtained, and a silver-stained SDS gel
showed the same two bands, one diffuse at 30 kDaplasmon resonance using a BIAcore biosensor (Biacore
AB). Goat anti-human IgG, g chain-specific (GHFC), was and a smaller band at 8–10 kDa. Although N-terminally
blocked, these proteins were subjected to CNBR diges-covalently coupled to research grade CM5 sensor chips
using a standard amine coupling procedure and re- tion in situ and a partial sequence was determined (not
shown). Both bands were identified as murine monocyteagents, according to the manufacturer’s instructions. Cpv
p32/Fc (30–50 mg/ml) was injected over the immobilized chemotactic protein-1 (MCP1), a chemokine of the b
class. The bands differed in the extent of glycosylationGHFC, and concentrated (3.5- to 10-fold) conditioned me-
dium (30 ml) from cell lines (including TE71) was indepen- and proteolytic processing.
dently passed over a GHFC-coated chip (negative con-
Affinity measurements of recombinant MCP1trol) as well as a cpv p32/Fc-coated GHFC chip at a flow
for cpv p32rate of 3 ml/min. Similarly, purified chemokines (0.2 and
10 mg/ml) were passed over both surfaces at 5 ml/min.
To accurately determine the affinity and specificity of
Regeneration of the chip was accomplished with one 10-
MCP1 for cpv p32, we used a combination of cellular
ml pulse of 100 mM phosphoric acid at 10 ml/min. All
and solid-phase binding assays with recombinant mu-
binding was performed in HBS (10 mM HEPES, 0.15 M
rine MCP1, radiolabeled without significant loss of bio-
NaCl, 3.4 mM EDTA, 0.02% NaN3 , 0.005% surfactant P2O, logical activity. 125I-muMCP1 showed saturation binding
pH 7.4).
to cpv p32/Fc immobilized in 96-well plates, with an
affinity constant (Kd) of 0.083 nM (Fig. 3A). UnlabeledRESULTS
muMCP1 and flag p32, but not purified flag peptide,Construction of viral fusion chimeras and biosensor
completely inhibited 125I-muMCP1 binding to immobi-screening of conditioned medium from diverse cell
lized cpv p32/Fc with inhibitory constants of 0.037 andpopulations
0.13 nM (Fig. 3B). To test whether p32 could inhibit MCP1
The complete sequence of the 35K gene from cowpox binding to MCP1 receptors, we used THP1 cells, a hu-
virus (Brighton Red strain) was expressed both as an N- man macrophage line known to express MCP1 recep-
terminally octapeptide-tagged (‘‘flag’’) protein and as a tors (CCR2b), as a source of native receptors. 125I-
C-terminally fused Fc chimera. Similar constructs were muMCP1 showed saturation binding isotherms to THP1
made and expressed of the corresponding gene product cells (Fig. 3C), with 7015 high-affinity sites (Kd  0.82
(G5R) from variola virus (vav; Fig. 1A). The apparent mo- nM). Binding was similarly completely and specifically
lecular masses of the flag cpv and variola proteins on inhibited by unlabeled recombinant muMCP1 (KI  1.0
reducing SDS gels are 32 and 35 kDa, respectively, and nM) as well as by both forms of cpv p32 (Fig. 3D). As
those of the corresponding Fc chimeric protomers were the KI of flag p32 and p32/Fc was 100 and 13 pM, respec-
58 and 61 kDa. Most of the initial experiments used the tively, cpv p32 binds (and inhibits) muMCP1 with an affin-
cpv Fc chimera, and we refer to the cpv core protein ity at least 10-fold higher than that at which muMCP1
as p32. Both chimeras were tested for surface binding binds its own cellular receptors.
against a panel of 164 cell lines by FACS analysis, with-
out success (not shown). Since the p32 cognate might CPV p32 binds b chemokines promiscuously with
be a secreted cellular protein with no surface form, we high affinity but binds a and g chemokines
also tested conditioned medium (CM) from these cell with low affinity or not at all
lines using surface plasmon resonance technology (BIA-
To test cpv p32 binding to a variety of chemokines, ascore, Pharmacia). Figure 1B shows the specific reso-
well as to assess potential cross-competition issues, wenance produced by a chip containing immobilized cpv
examined a total of 29 recombinant chemokines repre-p32/Fc (captured through coupled goat anti-human Fc
senting all three known classes, as well as C5a, theantibody) when exposed to CM from a murine thymic
complement C5 anaphylatoxin cleavage product withepithelial line, TE71, suggesting that a specific p32
strong chemotactic activity, in two assays: competitioncounter structure(s) is present in the CM.
assays to detect inhibition of MCP1 binding, and BIAcore
Identification and purification of CPV p32 cognate screening to detect direct binding. Figure 4 depicts typi-
from TE71 cell supernatants cal inhibition assays of 125I-muMCP1 binding to immobi-
lized cpv p32/Fc with unlabeled muMPC1, human eo-To determine if the putative p32 cognate is a product
of TE71 cells, these cells were metabolically labeled with taxin, murine MIP1a (b chemokines), human Groa, and
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FIG. 1. Specific binding to cpv p32 detected in TE71 medium by plasmon resonance. (A) SDS gels (reducing conditions) of purified recombinant
flag-cpv p32 (lane 1), flag-vav p35 (lane 2), cpv p32/Fc (lane 3), and vav p35/Fc (lane 4). Markers at left. Proteins were affinity-purified as described
under Materials and Methods. (B) Cpv p32/Fc was immobilized to the BIAcore chip via a capture antibody (goat anti-human Fc) and exposed to
conditioned medium from the TE71 cell line, as described under Materials and Methods. The specific response is plotted as resonance units (RU)
vs time (sec) and incorporates subtraction of the nonspecific signal from CM independently passed over a chip containing only the capture antibody.
The decay characteristic of the response represents slow dissociation of the CM cognate protein from cpv p32, and the leading shoulder represents
its association.
interleukin 8 (both a chemokines). MCP1, human eotaxin over 125I-muMCP1 (see also Fig. 6B for variola vCCI), and
IL8 showed only very-low-affinity binding (Kd  0.05 mM).and MIP1a bound with high affinity [Kd (muMCP1)  37
pM; Kd (huEotaxin)  91 pM; Kd (muMIP1a)  83 pM] Complete cell and plate binding data are summarized in
Table 1, along with results from the Biosensor screen.and showed cross-competition for binding to p32, sug-
gesting a common binding site. Groa, however, produced Virtually all 16 b chemokines bound p32, clearly de-
tected by induced resonance signals on the BIAcore, andno detectable inhibition even at a 5000-fold molar excess
completely inhibited 125I-muMCP1 binding to immobilized
p32 in plates. None of the 13 members of the a or g
classes (or C5a) showed detectable direct binding activ-
ity in the Biosensor. These included the following: human
platelet factor 4 (PF-4), huIP-10, huGROa, b and g, rat
GROa, huIL-8, huSDF1-b, huNAP-2, huMIG, muMIP2,
muKC, huENA-78, huIL-16 (cytokine with chemoattractant
properties); human lymphotactin (g chemokine); huC5a
(complement), and human midkine, a 15-kDa cytokine
that induces neurite outgrowth and displays (chemokine-
like) heparin-binding characteristics. The more sensitive
plate inhibition assay, however, detected low-affinity IL8
binding (Kd  0.05 mM), no binding for 11 other a chemo-
kines, and only limited inhibition with huMIG and lympho-
tactin even at 5000-fold molar excess, precluding an esti-
FIG. 2. Metabolic labeling of TE71 cell line and purification of cpv
mate for their affinities.p32 secreted cognate. (A) TE71 cells were 35S-labeled for 30 min at
377, supernatants were immunoprecipitated with cpv p32/Fc or control
CPV p32 specifically inhibits MCP1-mediatedreagents, and immunoprecipitates were resolved on an 8–18% SDS
gel, as described under Materials and Methods. Lane 1 (control), hu- chemotaxis and calcium flux in a dose-dependent
IgG1; lane 2, cpv p32/Fc; lane 3 (control), huTNFRII/Fc. Arrows mark the manner
position of diffuse 30-kDa and sharp 8- to 10-kDa proteins specifically
immunoprecipitated by cpv p32/Fc. Markers appear at left. (B) Silver- To examine the ability of cpv p32 to inhibit chemokine-
stained SDS gel of purified proteins from TE71 CM. 20 mg of p32 induced biological responses, two assays were used.
cognate protein was affinity-purified from 2.1 liters of CM, as described First, the classic chemokine-mediated monocyte chemo-
under Materials and Methods. Lane 1, unfractionated CM from TE71
taxis assay was exploited using a mixed population ofshowing prominent albumin band at 60 kDa; lane 2, proteins affinity-
PBMC and recombinant muMCP1 (with or without vary-purified with cpv p32/Fc showing diffuse 30-kDa and sharp 8- to 10-
kDa bands. ing concentrations of p32/Fc or IgG1 control) in opposite
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FIG. 3. Equilibrium binding isotherms of recombinant cpv p32 and 125I-muMCP1. (A) Saturation binding of 125I-muMCP1 to immobilized p32/Fc in
plates. Inset shows data replotted in Scatchard format. r, molecules bound (times 6 1 108); C, free molar concentration of 125I-muMCP1. Kd  83
pM. (B) Inhibition assays using plate-immobilized p32/Fc, 125I-muMCP1 (0.5 nM) in solution, and flag-p32 (l), muMCP1 (j), or flag peptide (m) as
competitive inhibitors. I, inhibition; C, molar concentration of inhibitor. Cpv p32 shows complete inhibition while flag peptide control shows none.
(C) Saturation binding of 125I-muMCP1 to THP1 macrophage cells. Inset shows data replotted in Scatchard format. r, molecules bound/cell; C, free
molar concentration of 125I-muMCP1. (D) Inhibition assays using THP1 cells, 125I-muMCP1 (0.5 nM), and unlabeled muMCP1 (j), flag-p32 (l), or
cpv p32/Fc (m) as inhibitors. The amount of 125I-muMCP1 chosen filled only the high-affinity class of sites. r, molecules bound/cell; C, free molar
concentration of inhibitor. See Materials and Methods for details.
wells of a modified Boyden chamber (Martinet et al., assessed by confocal fluorescence scanning micros-
copy. MCP1 specifically induced a dose- and time-de-1994). After incubation for 1 hr at 377, cells that migrated
to the lower well were counted, and results were plotted pendent fluorescence burst in THP1 cells loaded with
fluo-3 reporter, indicating Ca2/ flux, and 100 ng/ml con-as ‘‘number of cells migrated’’ vs inhibitor concentration
(Fig. 5A). p32/Fc, but not IgG1, clearly inhibited monocyte centrations of MCP1 could be completely inhibited by a
molar equivalence cpv p32 of either construct (Fig. 5B).chemotaxis in a dose-dependent manner, with the molar
equivalence of p32 to MCP1 producing complete inhibi- Thus, CPV p32 is an efficient and specific inhibitor of
chemokine-induced biological responses.tion. The IgG1 control measures the number of mono-
cytes present in the absence of MCP1 (background).
Conventional checkerboard analysis clearly demon- Variola p35 also binds b chemokines specifically
strated that monocyte migration was chemotactic (not
chemokinetic or random), since migration occurred in The variola virus equivalent of cpv p32 is a 253-amino-
acid open reading frame, termed G5R in the India 1967the presence of a concentration gradient of MCP1 toward
the point of highest concentration (not shown). strain, and is 85% identical in sequence, including con-
served leader segments, eight cysteines, and the singleSecond, the ability of p32 to inhibit muMCP1-induced
Ca2/ mobilization in the huTHP1 macrophage line was potential N-linked glycosylation site. It is localized near
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TABLE 1the right genome terminus. A recombinant G5R/Fc con-
struct was synthesized, expressed in mammalian cells, Summary of Promiscuous b Chemokine Binding to vCCI
purified, and tested for the ability to specifically bind
Cell-based assaymuMCP1 in a plate binding assay (Fig. 1A). Figure 6A
shows that G5R/Fc binds 125I-muMCP1 with saturation Inhibitor Ki (nM ) BIACore binding
isotherms and high affinity (Kd  1.0 nM). The inhibition
mu MCP-1 1.000assay in Fig. 6B, involving immobilized G5R/Fc and 125I-
CPVp32/Fc 0.013muMCP1, documents that both unlabeled muMCP1 and
flag p32 0.100human eotaxin (b chemokines) cross-compete, as was
shown for cpv p32/Fc (Table 1), and with similar affinities
Plate assay
[KI (MCP1)  1.0 nM; KI (eotaxin)  1.25 nM].
Mouse
MCP-1 0.037 /DISCUSSION
MCP-5 0.053 /
MIP-1a 0.083 /We have demonstrated the p32 protein from cpv,
MIP-1b 0.060 /whose equivalent in vaccinia is the 35-kDa virulence pro-
C10 0.441 /
tein (Patel et al., 1990), is a virtually universal inhibitor of Eotaxin 0.347 /
chemokines of the b (but not a or g) class. The variola Human
MCP-1 2.381 /equivalent (G5R), 85% identical in sequence, appears to
MCP-2 0.526 0have the same properties, and we have therefore termed
MCP-3 0.157 /the gene product vCCI (viral C-C chemokine inhibitor)
MCP-4 0.126 /
to reflect this crucial and general characteristic. vCCI Rantes 0.096 /
specifically binds b chemokines with high affinity and Eotaxin 0.091 /
MIP-1a 0.080 /completely inhibits MCP1 biological activity and binding
Ratto a known cellular receptor for MCP1 and MCP3 (Charo
MCP-1 0.023 /et al., 1994; Franci et al., 1995) Further, since we show
MIP-1a 0.005 /
all that 35K-binding chemokines also competitively inhibit Rantes n.d. /
MCP1 binding, they presumably share a common binding
Note. The top part of the table shows the results for the THP1 cell-site on the viral protein, making it likely that vCCI also
based inhibition assay with 125I-muMCP1. See also Figs. 3 and 4 forgenerally inhibits chemokine binding to cellular recep-
details. The bottom part of the table shows results for solid-phasetors, and hence biological activity. The most accurate
inhibition (plate) or direct binding (BIAcore) assays with immobilized
measure of vCCI affinity for muMCP1 (Kd  13–100 pM), cpv p32/Fc. A plus sign denotes a clear resonance signal on BIAcore.
based on 125I-muMCP1 inhibition against cellular recep- I, inhibition; Ki , inhibition constant, n.d., not determined. A total of 13
a or g chemokines, C5a, IL16, and huMidkine were also tested andtors, is at least 10-fold higher than the affinity that MCP1
showed no binding in the BIAcore and poor or no binding in platedisplays for its own native receptors, providing evidence
assays (see text for list and Methods and Materials for details.)
that vCCI is a potent general inhibitor of b chemokine
activity. Rat MIP1a, for example, shows an even higher
affinity (Kd  5 pM; Table 1).
The proposed primary viral function of vCCI is competi-
tive inhibition of an entire class of proinflammatory host
(b) chemokines elicited by viral infection itself. The selec-
tive advantage is increased virulence arising from, in
effect, partial immunosuppression of the host. Evidence
that b chemokines serve a proinflammatory role in nor-
mal immune responses is strong. They are induced early
and are chemoattractive to mononuclear and antigen-
presenting dendritic cells, lymphocytes, and eosinophils,
but they also mediate immunoenhancing effects by act-
ing as costimulants of lymphocyte cytolysis, proliferation,
and cytokine production (Baggiolini et al., 1994; Murphy,
FIG. 4. Representative inhibition assays with immobilized cpv p32/ 1996). Blocking antibodies to MIP1a, for example, re-
Fc reflecting chemokine class-specific binding. Inhibition assays used duces the severity of experimental autoimmune enceph-
immobilized cpv p32/Fc and 125I-muMCP1 (0.5 nM) in solution with and
alomyelitis in mice (Karpus et al., 1995). Direct evidencewithout unlabeled muMCP1 (j), human eotaxin (m), or muMIP1a (l)
for antiviral effects of b chemokines comes from experi-(b chemokines), huGroa (h), or IL-8 (l) (both a chemokines). I, inhibi-
tion; C, free molar concentration of inhibitor. ments with MIP1a knock-out mice challenged with either
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FIG. 5. Inhibition of MCP1-induced cellular responses by cpv p32. (A) HuMCP1-induced macrophage chemotaxis was measured in modified
Boyden chambers using unfractionated human PBMC. Upper chambers contained 5 1 106 cells, and lower chambers contained 50 ng/ml of
recombinant huMCP1 with or without varying concentrations of cpv p32/Fc (L) or huIgG1 control (h). The p32 protein completely inhibited all
migration at molar equivalence. Migrations were determined to be macrophage-specific and occurred only in the direction of increasing MCP1
concentrations. See Materials and Methods for details. (B) HuMCP1-induced Ca2/ mobilization in huTHP1 macrophage cells was measured by
fluorescence in fluo-3 (reporter)-loaded cells, quantified as mean fluorescence intensity (MFI) using confocal fluorescence microscopy. See Materials
and Methods for details. The MFI from 100 ng/ml of MCP1 (j) was inhibited in a dose-dependent manner by cpv p32/Fc (l, 100 ng/ml; m, 1 mg/
ml; l, 10 mg/ml), while p32/Fc alone induced no detectable change in fluorescence even at 10 mg/ml (h).
coxsackie or influenza virus: post-coxsackie-induced a rationale for the general failure of vCCI to effectively
inhibit members of the other two known classes of chem-myocarditis and resistance to influenza infection are both
severely reduced (Cook et al., 1995). Conversely, the sim- okines (a and g) is less clear. Classically, b chemokines
are strongly chemoattractive for monocytes/macro-ple existence of the vCCI gene suggests that other b
chemokines may also have antiviral activity. In contrast, phages and eosinophils and activate T cells, but do not
FIG. 6. Variola p35/Fc also binds b chemokines. (A) Equilibrium binding isotherms with plate-immobilized variola virus p35/Fc and 125I-muMCP1.
Inset shows data replotted in Scatchard format. r, molecules bound; C, free molar concentration of 125I-muMCP1. (B) Inhibition of 125I-muMCP1 (0.5
nM) binding to immobilized variola p35/Fc with unlabeled muMCP1 (j), human eotaxin (l), or mouse eotaxin (m) (b chemokines), or huGroa (s).
I, inhibition; C, molar concentration of inhibitor. See Table 1 and Materials and Methods.
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affect neutrophils, while the reverse is true for a chemo- recombinant vCCI protein (both cowpox virus and variola)
with high affinity, while none of the 13 a chemokineskines. Thus, potent viral inhibition of infiltration involving
multiple populations is no doubt one selective advantage showed detectable binding in the BIAcore system. A low-
affinity interaction could, however, be detected in theconferred by vCCI. However, proinflammatory character-
istics have been noted for the a class as well. Chemo- more sensitive plate binding inhibition assay for IL8 (Kd
 50 nM; Fig. 4) and unmeasurably lower affinities forkines share 25–80% identity in sequence and differ con-
spicuously in the spacing of the first two of four invariant human MIG and lymphotactin (g chemokine). All chemo-
kines were previously shown to be biologically activecysteines (b, C-C; a, C-x-C). Although formally possible,
it seems unlikely that mutations which eliminate binding with in vitro assays by the vendor. Unlike Graham et
al. (1997), we conclude that vCCI chemokine binding isto those classes would be neutral. More likely is that an
unknown selective advantage is accrued, the nature of preferentially b-specific and the physiologically im-
portant class from the viral perspective. Second, we di-which awaits a more complete understanding of chemo-
kine action. rectly demonstrate, by two different assays, that vCCI is
a potent competitive inhibitor of MCP1 binding to cellularThe genomic location of vCCI in poxviruses is also
consistent with a virulence function. Poxviruses contain chemokine receptors and biological activity (chemotaxis
and induced calcium flux). As stated above, since welarge duplex DNA genomes (160–340 kb), covalently
closed hairpin termini, and 10-kb inverted terminal re- show that all 35K binding chemokines also competitively
inhibit MCP1 binding to the viral protein, it seems likelypeats (ITRs) in or near which most virulence genes tend
to cluster. In orthopoxviruses, such as cowpox, vaccinia, that vCCI also generally inhibits chemokine binding to
cellular receptors, and hence biological activity. Grahamor rabbit pox, and leporipoxviruses, such as Shope fi-
broma (Sfv), vCCI is also ITR-localized (diploid), terminus- et al. infer this indirectly from the changes in tissue pa-
thology that they report, using a recombinant rabbitpoxproximal, extremely conserved in sequence, and ex-
pressed at both early and late times, consistent with virus inactivated at the 35K virulence gene locus. How-
ever, some of these authors have previously publishedthe proposed virulence function. Although variola lacks
protein-encoding ITRs, the analogous gene in both se- similar work which reached the opposite conclusion
(Martinez-Pomares et al., 1995). Martinez-Pomares andquenced strains is the right terminus-proximal ORF G5R
(India, 1967) and G3R (Bangladesh). These two ORFs colleagues using the same poxvirus (rabbitpox) inacti-
vated at the same locus (35K) infecting the same hostpurportedly differ by a single amino acid (Massung et
al., 1993; Shchelkunov et al., 1993), and are 85% identical (European rabbit) reported neither gross nor microscopic
histopathological host differences between the knock-to vCCI from the orthopoxviruses cpv and vaccinia (vv).
Widely cultured laboratory strains of vv (e.g., WR) have out and the wild-type virus infections. These authors con-
cluded this protein does not play a major role in thea disrupted vCCI gene and often disruptions of other
virulence genes as well, such as T2 (Smith and Goodwin, virulence of virus. Thus, the histopathology data are am-
biguous. Third, the vCCI affinity estimate by Graham et1994) and CrmC (both soluble TNF receptors), consistent
with their roles independent of viral replication (Smith al. for a b chemokine (Kd  73 nM) is almost 1000-fold
lower than that which we measure (Kd  0.1 nM) andand Goodwin, 1994). Thus, the clear prediction is that
vCCI will be found in most poxviruses, including monkey 50-fold less than published affinities between chemo-
kines and cellular receptors. The large discrepancy in bpox, as yet unsequenced.
While our paper was being submitted, related work by chemokine affinity is likely accounted for by the quality
and sensitivity of the assays: cell-based inhibition assaysGraham et al. (1997) appeared, describing characteris-
tics of presumably the same gene product described and plate binding assays using a capture antibody (our
data) or plate binding assays lacking a capture antibodyhere. Our data, however, differ markedly from their re-
sults in several respects. First, Graham et al. report that (Graham et al., 1997).
Perhaps the most intriguing feature of vCCI is its com-this gene product, or a similar gene product, from cpv,
vaccinia, and myxoma binds chemokines with broad plete lack of sequence homology with any known chemo-
kine receptor, all of which are G-coupled, seven-mem-specificity representing two classes (a, b), although data
from only a single member of each class were actually brane-spanning proteins with strong sequence homology
(24–80%) among themselves (Charo et al., 1994; Francipresented (IL8, a class; RANTES, b class). The authors
chiefly relied on chemical cross-linking of 125I-hu IL8 or et al., 1995; Gerard and Gerard, 1994; Neote et al., 1993;
Probst et al., 1992). This contrasts sharply with many125I-RANTES to proteins in crude supernatants from pox-
virus-infected cells. In contrast, we used purified, well- other virulence proteins in poxviruses, including soluble,
secreted receptors for TNF (T2 and CrmC, encoded atcharacterized recombinant vCCI protein expressed in
two different forms from each of two different poxviruses, distinct loci), interferons g and a, and IL-1. These clearly
represent acquired forms of the cellular receptor genes,and four different binding assays involving 30 purified
recombinant chemokines covering three species subverted to viral function as competitive inhibitors, and
they show marked sequence homology to their analogs.(mouse, human, and rat). We found that all 16 recombi-
nant b chemokines tested in multiple assays bound our No such ancestral relation seems possible with vCCI.
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FIG. 7. Sequence alignment of vCCI from cowpox, variola, vaccinia, and Shope fibroma viruses. Cysteines are enclosed in black boxes; residues
that are conserved in all four viruses are shaded gray. Asterisks indicate the positions of acidic residues in at least two family members.
Although at least one virulence gene in cytomegalovirus tures of mature vCCI provide modest clues: eight cys-
(CMV) encodes a protein (US28) known to bind MIP1a, teines (presumably four disulfides) and several three- to
b and RANTES (b chemokines), US28 is structurally a five-residue motifs are absolutely conserved, one poten-
classic chemokine receptor showing dramatic sequence tial N-linked glycosylation site, and a strongly acidic na-
homology and multiple membrane-spanning elements ture, represented as acidic patches throughout the mole-
(Neote et al., 1993). Indeed, extensive mutagenesis and cule (Fig. 7). Many b chemokines, including MCP1, are
deletion studies of known chemokine receptors (Hebert quite basic, suggesting that salt links between ligand
et al., 1993; Horuk, 1994; Lu et al., 1995) imply a ligand and vCCI are important. Some acidic clusters are also
binding site composed of discontinuous extracellular seen at the (extracellular) N-terminus of many (but not
loops adopting a membrane-stabilized conformation, all) chemokine receptors, although mutagenesis studies
suggesting that construction of an effective soluble form suggest that they are more relevant to specificity than
is impossible. It seems more likely, therefore, that vCCI affinity. The mature leporipoxvirus Sfv vCCI shows an 18-
may be the product of a kind of ‘‘phage display’’ system amino-acid apparent insertion element not found in the
in poxviruses, where relentless shuffling of sequences, orthopoxviruses cpv, vav, and vv, but the peptide is only
under inexorable selective pressure, gave rise to a com- slightly acidic and contains no extra cysteines. Since Sfv
pletely new protein with similar binding activity to native vCCI does, however, share only 42% identity with the
chemokine receptors. Alternatively, a formal possibility orthopoxvirus members (85% identical among them-
remains that vCCI represents a new class of cellular selves), it is conceivable that its chemokine binding spec-
chemokine receptors as yet unidentified. ificity may vary from cpv or variola. Nonetheless, such
divergence is similar to the sequence divergence seenThe structural basis for b chemokine binding to vCCI
between other virulence factors of different pox speciesis unclear. The virulence factor shows no sequence ho-
which nevertheless retain almost identical functions andmology to any protein in public databases, and at any
cognate specificities (Hu et al., 1994; Smith and Goodwin,rate even the nature of chemokine-cellular receptor inter-
actions remains obscure. The strongly conserved fea- 1994; Spriggs et al., 1992).
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two copies of an early gene encoding a soluble secreted form ofThe vCCI protein not only adds a new perspective to
the type II TNF receptor. Virology 204, 343–356.the genesis of viral immunomodulators, it also proves
Karpus, W. J., Lukacs, N. W., McRae, B. L., Strieter, R. M., Kunkel, S. L.,
the existence of soluble, broad spectrum chemokine in- and Miller, S. D. (1995). An important role for the chemokine macro-
hibitors, something previously thought impossible. Crys- phage inflammatory protein-1 alpha in the pathogenesis of the T
cell-mediated autoimmune disease, experimental autoimmune en-tallographic studies are now possible on chemokine/
cephalomyelitis. J. Immunol. 155, 5003–5010.vCCI complexes and may be relevant to chemokine/cel-
Kotwal, G., and Moss, B. (1988). Vaccinia virus encodes a secretorylular receptor interactions. It is interesting to note the
polypeptol structurally related to complement control proteins. Na-
recent discovery of a 20-amino-acid peptide erythropoie- ture 335, 176–178.
tin mimetic, which, while showing no sequence homol- Kotwal, G. J., Isaacs, S. N., McKenzie, R., Frank, M. M., and Moss, B.
(1990). Inhibition of the complement cascade by the major secretoryogy to native erythropoietin, nevertheless displays similar
polypeptide of vaccinia virus. Science 250, 827–830.biological activities and binds soluble erythropoietin re-
Laemmli, U. K. (1970). Cleavage of structural proteins during the assem-ceptor with contacts reminiscent of the native ligand (Liv-
bly of the head of bacteriophage T4. Nature 227, 680–685.
nah et al., 1996; Wrighton et al., 1996). Finally, it is clearly Livnah, O., Stura, E. A., Johnson, D. L., Middleton, S. A., Mulcahy, L. S.,
possible that vCCI, or its derivatives, may prove therapeu- Wrighton, N. C., Dower, W. J., Jolliffe, L. K., and Wilson, I. A. (1996).
Functional mimicry of a protein hormone by a peptide agonist: Thetically useful in human disease.
EPO receptor complex at 2.8 A. Science 273, 464–471.
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